AKT1 and chondrosarcoma: Shikonin and its derivatives can inhibit phosphorylation-signal transducer and activator of transcription 3 (p-STAT3), and increase the activation of phosphorylation-protein kinase B (P-AKT), mitogen-activated protein kinases (MAPKs), phosphorylation-extracellular regulated protein kinases (P-ERK), phosphorylation-c-Jun N-terminal kinase (P-JNK), and P-p38 MAPK for chondrosarcoma treatment in a dose-dependent manner [39].